| Status | Study |
| NOT_YET_RECRUITING |
Study Name: REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation Condition: Date: 2023-06-05 Interventions: 28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54Gy) which will occur over approxim |
| Recruiting |
Study Name: Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) Condition: Radiation Therapy Cancer Cancer of A Date: 2017-04-24 |
| Not yet recruiting |
Study Name: Study of Pomalidomide in Anal Cancer Precursors Condition: High Grade Squamous Intra-epithelial Lesion (HSIL) Date: 2017-03-08 Interventions: Drug: Pomalidomide 2 MG Oral Capsule [Pomalyst] Pomalidomide is an oral immunomodulatory derivative of t |
| Not yet recruiting |
Study Name: Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Condition: Vulvar Cancer Cervical Cancer Vulvar Dysplasia Date: 2017-02-17 Interventions: Procedure: Screening anal Pap smear - No high-resolution anoscopy |
| Recruiting |
Study Name: Proton Therapy in Reducing Toxicity in Anal Cancer Condition: Anus Neoplasms Date: 2017-01-10 Interventions: Radiation: Proton therapy Prim |
| Not yet recruiting |
Study Name: Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Condition: Breast Carcinoma Head and Neck Cancer Melanoma (Skin) Date: 2016-12-16 Interventions: Drug: Indocyanine green Other |
| Recruiting |
Study Name: Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas Condition: Cervical Cancer Vulvar Cancer Anal C Date: 2016-11-30 Interventions: Other: CaptHPV method 10 ml of blood sample will be made b |
| Recruiting |
Study Name: Prospective Cohort on Quality of Sexual Life Among Men Who Have Sex With Men Treated for Anal Cancer With Concurrent Chemotherapy and Intensity-modulated Radiotherapy Condition: Anal Cancer Quality of Life Date: 2016-10-25 Interventions: Behavioral: Quality of life and quality of sexual life questionnaires |
| Recruiting |
Study Name: HOUSTON - HPV-related Oropharyngeal and Uncommon Cancers Screening Trial Of Men Condition: Malignant Neoplasms of Digestive Organs Malignant Neoplasms of Lip Oral Cavity and Pharynx Date: 2016-09-07 Interventions: Procedure: Oropharyngeal Cancer Screening |
| Recruiting |
Study Name: Pembrolizumab in Refractory Metastatic Anal Cancer Condition: Anal Cancer Date: 2016-09-02 Interventions: Drug: Pembrolizumab Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. |